Glycobiology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
Description
The global glycobiology market is experiencing remarkable growth, fueled by advancements in biomedical research, increasing applications in drug development, and the growing demand for innovative diagnostic and therapeutic solutions. The market is projected to reach US$ 2.1 billion by 2025 and is anticipated to grow to US$ 5.9 billion by 2032, expanding at a CAGR of 15.9% during the forecast period.
Market Insights
Glycobiology focuses on the study of glycans-complex carbohydrates found in all living organisms. These molecules are essential to cellular function, influencing processes such as protein folding, immune responses, and cell signaling. Glycosylation, the enzymatic process that attaches glycans to proteins or lipids, is among the most critical modifications required for cell survival and is increasingly being studied for its role in diseases like cancer, autoimmune disorders, and infectious conditions.
As pharmaceutical and biotechnology companies intensify their focus on glycoproteins and carbohydrate molecules, demand for advanced analytical tools and enzymatic solutions continues to surge. The adoption of glycobiology technologies is also accelerating in vaccine development and monoclonal antibody production, positioning the sector for sustained expansion.
Key Market Drivers
A key driver of growth is the rising global incidence of infectious and degenerative diseases, which has heightened the need for novel therapeutics and vaccines. Glycobiologic enzymes such as glycosidases play a crucial role in the formulation of antiviral drugs, notably in preventing the spread of viruses like influenza.
In autoimmune diseases such as rheumatoid arthritis and multiple sclerosis, recombinant monoclonal antibodies (rMAbs)-which are glycoproteins-are increasingly used for treatment, further driving enzyme demand. Additionally, rising investment in R&D by government bodies and private firms is supporting innovation and expanding the scope of glycobiology applications.
Business Opportunity
The market presents significant opportunities for companies offering tools for structural glycan analysis. Technological innovation in mass spectrometry, nuclear magnetic resonance (NMR), and enzymatic profiling is enabling researchers to gain deeper insights into glycan structures and functions. Businesses are strategically aligning through partnerships and co-marketing agreements to offer integrated solutions and reach broader customer bases in academia, pharma, and diagnostics.
Regional Outlook
• United States: The U.S. market continues to dominate, driven by strong R&D infrastructure, presence of key market players such as Thermo Fisher Scientific, Merck KGaA, and Agilent Technologies, and increased adoption of advanced glycobiology tools in research institutions and biopharma companies.
• United Kingdom: The U.K. is emerging as a hub for glycan structure research using advanced techniques like NMR spectroscopy. Academic institutions are leveraging these tools to enhance understanding of microbial interactions and therapeutic applications.
• China: Rapid investment in life sciences research and national R&D programs is fostering the growth of glycobiology in China. The government’s emphasis on biotechnology advancement is helping address skill gaps and infrastructure challenges.
Competitive Analysis
The market is moderately consolidated, with key players focusing on product innovation, collaborations, and geographical expansion. Companies like Bruker Corporation, Bio-Techne, RayBiotech Life, and New England Biolabs are introducing new instruments and enzymes to support glycan analysis and profiling. Partnerships between mass spectrometry platform developers and biotechnology firms are expanding the market reach and accelerating product development cycles.
Key Companies Covered
• Glycodiag
• Tracxn Technologies Limited
• Agilent Technologies, Inc.
• Takara Bio Inc.
• Bio-Techne
• Bruker Corporation
• Thermo Fisher Scientific Inc.
• Shimadzu Corporation
• New England Biolabs.
• Waters.co.
• Merck KGaA
• Palleon Pharmaceuticals
• Asparia Glycomics
• RayBiotech Life,Inc.
• Z Biotech,LLC.
• Chemily Glycoscience
• Lectenz Bio
• 2BScientific
Recent developments include:
• Thermo Fisher Scientific partnering with TransMIT GmbH to expand spatial multi-omics applications in clinical labs.
• Bruker launching a MALDI HiPLEX-IHC tissue imaging solution to support glycomic and proteomic studies using mass spectrometry.
Market Segmentation
By Product:
• Instruments
• Enzymes
• Consumables
• Kits and Reagents
By Enzyme:
• Galactosidases
• Fucosidases
• Chitinases
• Acetylgalactosaminidase
• Heparinase
• PNGase F
• Others
By Application:
• Drug Discovery and Development
• Diagnostic Applications
o Oncology
o Immunology
o Others
• Industrial Applications
• Therapeutic Applications
o Oncology
o Immunology
o Others
• Others
By End User:
• Biopharmaceutical Companies
• Research Laboratories
• Hospitals
• Diagnostic Centers
• Contract Research Organizations
• Biotechnology Industries
• Academic Institutes
• Others
By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa
Please note: Delivery Timelines - 5 working days.
Market Insights
Glycobiology focuses on the study of glycans-complex carbohydrates found in all living organisms. These molecules are essential to cellular function, influencing processes such as protein folding, immune responses, and cell signaling. Glycosylation, the enzymatic process that attaches glycans to proteins or lipids, is among the most critical modifications required for cell survival and is increasingly being studied for its role in diseases like cancer, autoimmune disorders, and infectious conditions.
As pharmaceutical and biotechnology companies intensify their focus on glycoproteins and carbohydrate molecules, demand for advanced analytical tools and enzymatic solutions continues to surge. The adoption of glycobiology technologies is also accelerating in vaccine development and monoclonal antibody production, positioning the sector for sustained expansion.
Key Market Drivers
A key driver of growth is the rising global incidence of infectious and degenerative diseases, which has heightened the need for novel therapeutics and vaccines. Glycobiologic enzymes such as glycosidases play a crucial role in the formulation of antiviral drugs, notably in preventing the spread of viruses like influenza.
In autoimmune diseases such as rheumatoid arthritis and multiple sclerosis, recombinant monoclonal antibodies (rMAbs)-which are glycoproteins-are increasingly used for treatment, further driving enzyme demand. Additionally, rising investment in R&D by government bodies and private firms is supporting innovation and expanding the scope of glycobiology applications.
Business Opportunity
The market presents significant opportunities for companies offering tools for structural glycan analysis. Technological innovation in mass spectrometry, nuclear magnetic resonance (NMR), and enzymatic profiling is enabling researchers to gain deeper insights into glycan structures and functions. Businesses are strategically aligning through partnerships and co-marketing agreements to offer integrated solutions and reach broader customer bases in academia, pharma, and diagnostics.
Regional Outlook
• United States: The U.S. market continues to dominate, driven by strong R&D infrastructure, presence of key market players such as Thermo Fisher Scientific, Merck KGaA, and Agilent Technologies, and increased adoption of advanced glycobiology tools in research institutions and biopharma companies.
• United Kingdom: The U.K. is emerging as a hub for glycan structure research using advanced techniques like NMR spectroscopy. Academic institutions are leveraging these tools to enhance understanding of microbial interactions and therapeutic applications.
• China: Rapid investment in life sciences research and national R&D programs is fostering the growth of glycobiology in China. The government’s emphasis on biotechnology advancement is helping address skill gaps and infrastructure challenges.
Competitive Analysis
The market is moderately consolidated, with key players focusing on product innovation, collaborations, and geographical expansion. Companies like Bruker Corporation, Bio-Techne, RayBiotech Life, and New England Biolabs are introducing new instruments and enzymes to support glycan analysis and profiling. Partnerships between mass spectrometry platform developers and biotechnology firms are expanding the market reach and accelerating product development cycles.
Key Companies Covered
• Glycodiag
• Tracxn Technologies Limited
• Agilent Technologies, Inc.
• Takara Bio Inc.
• Bio-Techne
• Bruker Corporation
• Thermo Fisher Scientific Inc.
• Shimadzu Corporation
• New England Biolabs.
• Waters.co.
• Merck KGaA
• Palleon Pharmaceuticals
• Asparia Glycomics
• RayBiotech Life,Inc.
• Z Biotech,LLC.
• Chemily Glycoscience
• Lectenz Bio
• 2BScientific
Recent developments include:
• Thermo Fisher Scientific partnering with TransMIT GmbH to expand spatial multi-omics applications in clinical labs.
• Bruker launching a MALDI HiPLEX-IHC tissue imaging solution to support glycomic and proteomic studies using mass spectrometry.
Market Segmentation
By Product:
• Instruments
• Enzymes
• Consumables
• Kits and Reagents
By Enzyme:
• Galactosidases
• Fucosidases
• Chitinases
• Acetylgalactosaminidase
• Heparinase
• PNGase F
• Others
By Application:
• Drug Discovery and Development
• Diagnostic Applications
o Oncology
o Immunology
o Others
• Industrial Applications
• Therapeutic Applications
o Oncology
o Immunology
o Others
• Others
By End User:
• Biopharmaceutical Companies
• Research Laboratories
• Hospitals
• Diagnostic Centers
• Contract Research Organizations
• Biotechnology Industries
• Academic Institutes
• Others
By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa
Please note: Delivery Timelines - 5 working days.
Table of Contents
275 Pages
- 1. Executive Summary
- 1.1. Global Glycobiology Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2025
- 1.5. Analyst Recommendations
- 2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. Porter’s Five Forces Analysis
- 2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
- 2.6. Impact of Ukraine-Russia Conflict
- 2.7. Economic Overview
- 2.7.1. World Economic Projections
- 2.8. PESTLE Analysis
- 3. Global Glycobiology Market Outlook, 2019-2032
- 3.1. Global Glycobiology Market Outlook, by Product, Value (US$ Bn), 2019-2032
- 3.1.1. Key Highlights
- 3.1.1.1. Instruments
- 3.1.1.2. Enzymes
- 3.1.1.3. Consumables
- 3.1.1.4. Kits and Reagents
- 3.2. Global Glycobiology Market Outlook, by Enzyme, Value (US$ Bn), 2019-2032
- 3.2.1. Key Highlights
- 3.2.1.1. Galactosidases
- 3.2.1.1.1. Fucosidases
- 3.2.1.1.2. Chitinases
- 3.2.1.1.3. Acetylgalactosaminidase
- 3.2.1.1.4. Heparinase
- 3.2.1.1.5. PNGase F
- 3.2.1.1.6. Others
- 3.2.1.2. GlcNAc Transferases
- 3.2.1.2.1. Acetylglucosaminyltransferase
- 3.2.1.2.2. Exostosin
- 3.2.1.2.3. Others
- 3.2.1.3. Fucosyltransferases
- 3.2.1.4. GalNAc Transferases
- 3.2.1.5. Galactosyl Transferases
- 3.2.1.6. Glucuronosyltransferases
- 3.2.1.7. Glucosyltransferases
- 3.2.1.8. Pentosyltransferases
- 3.2.1.9. Carbohydrate Kinases
- 3.2.1.10. Neuraminidases
- 3.2.1.11. Sialyltransferases
- 3.2.1.12. Others
- 3.3. Global Glycobiology Market Outlook, by Application, Value (US$ Bn), 2019-2032
- 3.3.1. Key Highlights
- 3.3.1.1. Drug Discovery and Development
- 3.3.1.2. Diagnostic Applications
- 3.3.1.2.1. Oncology
- 3.3.1.2.2. Immunology
- 3.3.1.2.3. Others
- 3.3.1.3. Industrial Applications
- 3.3.1.4. Therapeutic Applications
- 3.3.1.4.1. Oncology
- 3.3.1.4.2. Immunology
- 3.3.1.4.3. Others
- 3.3.1.5. Others
- 3.4. Global Glycobiology Market Outlook, by End User, Value (US$ Bn), 2019-2032
- 3.4.1. Key Highlights
- 3.4.1.1. Biopharmaceutical Companies
- 3.4.1.2. Research Laboratories
- 3.4.1.3. Hospitals
- 3.4.1.4. Diagnostic Centers
- 3.4.1.5. Contract Research Organizations
- 3.4.1.6. Biotechnology Industries
- 3.4.1.7. Academic Institutes
- 3.4.1.8. Others
- 3.5. Global Glycobiology Market Outlook, by Region, Value (US$ Bn), 2019-2032
- 3.5.1. Key Highlights
- 3.5.1.1. North America
- 3.5.1.2. Europe
- 3.5.1.3. Asia Pacific
- 3.5.1.4. Latin America
- 3.5.1.5. Middle East & Africa
- 4. North America Glycobiology Market Outlook, 2019-2032
- 4.1. North America Glycobiology Market Outlook, by Product, Value (US$ Bn), 2019-2032
- 4.1.1. Key Highlights
- 4.1.1.1. Instruments
- 4.1.1.2. Enzymes
- 4.1.1.3. Consumables
- 4.1.1.4. Kits and Reagents
- 4.2. North America Glycobiology Market Outlook, by Enzyme, Value (US$ Bn), 2019-2032
- 4.2.1. Key Highlights
- 4.2.1.1. Galactosidases
- 4.2.1.1.1. Fucosidases
- 4.2.1.1.2. Chitinases
- 4.2.1.1.3. Acetylgalactosaminidase
- 4.2.1.1.4. Heparinase
- 4.2.1.1.5. PNGase F
- 4.2.1.1.6. Others
- 4.2.1.2. GlcNAc Transferases
- 4.2.1.2.1. Acetylglucosaminyltransferase
- 4.2.1.2.2. Exostosin
- 4.2.1.2.3. Others
- 4.2.1.3. Fucosyltransferases
- 4.2.1.4. GalNAc Transferases
- 4.2.1.5. Galactosyl Transferases
- 4.2.1.6. Glucuronosyltransferases
- 4.2.1.7. Glucosyltransferases
- 4.2.1.8. Pentosyltransferases
- 4.2.1.9. Carbohydrate Kinases
- 4.2.1.10. Neuraminidases
- 4.2.1.11. Sialyltransferases
- 4.2.1.12. Others
- 4.3. North America Glycobiology Market Outlook, by Application, Value (US$ Bn), 2019-2032
- 4.3.1. Key Highlights
- 4.3.1.1. Drug Discovery and Development
- 4.3.1.2. Diagnostic Applications
- 4.3.1.2.1. Oncology
- 4.3.1.2.2. Immunology
- 4.3.1.2.3. Others
- 4.3.1.3. Industrial Applications
- 4.3.1.4. Therapeutic Applications
- 4.3.1.4.1. Oncology
- 4.3.1.4.2. Immunology
- 4.3.1.4.3. Others
- 4.3.1.5. Others
- 4.4. North America Glycobiology Market Outlook, by End User, Value (US$ Bn), 2019-2032
- 4.4.1. Key Highlights
- 4.4.1.1. Biopharmaceutical Companies
- 4.4.1.2. Research Laboratories
- 4.4.1.3. Hospitals
- 4.4.1.4. Diagnostic Centers
- 4.4.1.5. Contract Research Organizations
- 4.4.1.6. Biotechnology Industries
- 4.4.1.7. Academic Institutes
- 4.4.1.8. Others
- 4.5. North America Glycobiology Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 4.5.1. Key Highlights
- 4.5.1.1. U.S. Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 4.5.1.2. U.S. Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 4.5.1.3. U.S. Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 4.5.1.4. U.S. Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 4.5.1.5. Canada Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 4.5.1.6. Canada Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 4.5.1.7. Canada Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 4.5.1.8. Canada Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 4.5.2. BPS Analysis/Market Attractiveness Analysis
- 5. Europe Glycobiology Market Outlook, 2019-2032
- 5.1. Europe Glycobiology Market Outlook, by Product, Value (US$ Bn), 2019-2032
- 5.1.1. Key Highlights
- 5.1.1.1. Instruments
- 5.1.1.2. Enzymes
- 5.1.1.3. Consumables
- 5.1.1.4. Kits and Reagents
- 5.2. Europe Glycobiology Market Outlook, by Enzyme, Value (US$ Bn), 2019-2032
- 5.2.1. Key Highlights
- 5.2.1.1. Galactosidases
- 5.2.1.1.1. Fucosidases
- 5.2.1.1.2. Chitinases
- 5.2.1.1.3. Acetylgalactosaminidase
- 5.2.1.1.4. Heparinase
- 5.2.1.1.5. PNGase F
- 5.2.1.1.6. Others
- 5.2.1.2. GlcNAc Transferases
- 5.2.1.2.1. Acetylglucosaminyltransferase
- 5.2.1.2.2. Exostosin
- 5.2.1.2.3. Others
- 5.2.1.3. Fucosyltransferases
- 5.2.1.4. GalNAc Transferases
- 5.2.1.5. Galactosyl Transferases
- 5.2.1.6. Glucuronosyltransferases
- 5.2.1.7. Glucosyltransferases
- 5.2.1.8. Pentosyltransferases
- 5.2.1.9. Carbohydrate Kinases
- 5.2.1.10. Neuraminidases
- 5.2.1.11. Sialyltransferases
- 5.2.1.12. Others
- 5.3. Europe Glycobiology Market Outlook, by Application, Value (US$ Bn), 2019-2032
- 5.3.1. Key Highlights
- 5.3.1.1. Drug Discovery and Development
- 5.3.1.2. Diagnostic Applications
- 5.3.1.2.1. Oncology
- 5.3.1.2.2. Immunology
- 5.3.1.2.3. Others
- 5.3.1.3. Industrial Applications
- 5.3.1.4. Therapeutic Applications
- 5.3.1.4.1. Oncology
- 5.3.1.4.2. Immunology
- 5.3.1.4.3. Others
- 5.3.1.5. Others
- 5.4. Europe Glycobiology Market Outlook, by End User, Value (US$ Bn), 2019-2032
- 5.4.1. Key Highlights
- 5.4.1.1. Biopharmaceutical Companies
- 5.4.1.2. Research Laboratories
- 5.4.1.3. Hospitals
- 5.4.1.4. Diagnostic Centers
- 5.4.1.5. Contract Research Organizations
- 5.4.1.6. Biotechnology Industries
- 5.4.1.7. Academic Institutes
- 5.4.1.8. Others
- 5.5. Europe Glycobiology Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 5.5.1. Key Highlights
- 5.5.1.1. Germany Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 5.5.1.2. Germany Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 5.5.1.3. Germany Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 5.5.1.4. Germany Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 5.5.1.5. U.K. Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 5.5.1.6. U.K. Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 5.5.1.7. U.K. Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 5.5.1.8. U.K. Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 5.5.1.9. France Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 5.5.1.10. France Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 5.5.1.11. France Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 5.5.1.12. France Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 5.5.1.13. Italy Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 5.5.1.14. Italy Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 5.5.1.15. Italy Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 5.5.1.16. Italy Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 5.5.1.17. Turkey Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 5.5.1.18. Turkey Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 5.5.1.19. Turkey Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 5.5.1.20. Turkey Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 5.5.1.21. Russia Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 5.5.1.22. Russia Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 5.5.1.23. Russia Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 5.5.1.24. Russia Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 5.5.1.25. Rest of Europe Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 5.5.1.26. Rest of Europe Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 5.5.1.27. Rest of Europe Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 5.5.1.28. Rest of Europe Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 5.5.2. BPS Analysis/Market Attractiveness Analysis
- 6. Asia Pacific Glycobiology Market Outlook, 2019-2032
- 6.1. Asia Pacific Glycobiology Market Outlook, by Product, Value (US$ Bn), 2019-2032
- 6.1.1. Key Highlights
- 6.1.1.1. Instruments
- 6.1.1.2. Enzymes
- 6.1.1.3. Consumables
- 6.1.1.4. Kits and Reagents
- 6.2. Asia Pacific Glycobiology Market Outlook, by Enzyme, Value (US$ Bn), 2019-2032
- 6.2.1. Key Highlights
- 6.2.1.1. Galactosidases
- 6.2.1.1.1. Fucosidases
- 6.2.1.1.2. Chitinases
- 6.2.1.1.3. Acetylgalactosaminidase
- 6.2.1.1.4. Heparinase
- 6.2.1.1.5. PNGase F
- 6.2.1.1.6. Others
- 6.2.1.2. GlcNAc Transferases
- 6.2.1.2.1. Acetylglucosaminyltransferase
- 6.2.1.2.2. Exostosin
- 6.2.1.2.3. Others
- 6.2.1.3. Fucosyltransferases
- 6.2.1.4. GalNAc Transferases
- 6.2.1.5. Galactosyl Transferases
- 6.2.1.6. Glucuronosyltransferases
- 6.2.1.7. Glucosyltransferases
- 6.2.1.8. Pentosyltransferases
- 6.2.1.9. Carbohydrate Kinases
- 6.2.1.10. Neuraminidases
- 6.2.1.11. Sialyltransferases
- 6.2.1.12. Others
- 6.3. Asia Pacific Glycobiology Market Outlook, by Application, Value (US$ Bn), 2019-2032
- 6.3.1. Key Highlights
- 6.3.1.1. Drug Discovery and Development
- 6.3.1.2. Diagnostic Applications
- 6.3.1.2.1. Oncology
- 6.3.1.2.2. Immunology
- 6.3.1.2.3. Others
- 6.3.1.3. Industrial Applications
- 6.3.1.4. Therapeutic Applications
- 6.3.1.4.1. Oncology
- 6.3.1.4.2. Immunology
- 6.3.1.4.3. Others
- 6.3.1.5. Others
- 6.4. Asia Pacific Glycobiology Market Outlook, by End User, Value (US$ Bn), 2019-2032
- 6.4.1. Key Highlights
- 6.4.1.1. Biopharmaceutical Companies
- 6.4.1.2. Research Laboratories
- 6.4.1.3. Hospitals
- 6.4.1.4. Diagnostic Centers
- 6.4.1.5. Contract Research Organizations
- 6.4.1.6. Biotechnology Industries
- 6.4.1.7. Academic Institutes
- 6.4.1.8. Others
- 6.5. Asia Pacific Glycobiology Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 6.5.1. Key Highlights
- 6.5.1.1. China Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 6.5.1.2. China Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 6.5.1.3. China Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 6.5.1.4. China Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 6.5.1.5. Japan Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 6.5.1.6. Japan Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 6.5.1.7. Japan Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 6.5.1.8. Japan Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 6.5.1.9. South Korea Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 6.5.1.10. South Korea Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 6.5.1.11. South Korea Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 6.5.1.12. South Korea Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 6.5.1.13. India Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 6.5.1.14. India Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 6.5.1.15. India Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 6.5.1.16. India Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 6.5.1.17. Southeast Asia Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 6.5.1.18. Southeast Asia Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 6.5.1.19. Southeast Asia Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 6.5.1.20. Southeast Asia Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 6.5.1.21. Rest of Asia Pacific Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 6.5.1.22. Rest of Asia Pacific Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 6.5.1.23. Rest of Asia Pacific Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 6.5.1.24. Rest of Asia Pacific Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 6.5.2. BPS Analysis/Market Attractiveness Analysis
- 7. Latin America Glycobiology Market Outlook, 2019-2032
- 7.1. Latin America Glycobiology Market Outlook, by Product, Value (US$ Bn), 2019-2032
- 7.1.1. Key Highlights
- 7.1.1.1. Instruments
- 7.1.1.2. Enzymes
- 7.1.1.3. Consumables
- 7.1.1.4. Kits and Reagents
- 7.2. Latin America Glycobiology Market Outlook, by Enzyme, Value (US$ Bn), 2019-2032
- 7.2.1.1. Galactosidases
- 7.2.1.1.1. Fucosidases
- 7.2.1.1.2. Chitinases
- 7.2.1.1.3. Acetylgalactosaminidase
- 7.2.1.1.4. Heparinase
- 7.2.1.1.5. PNGase F
- 7.2.1.1.6. Others
- 7.2.1.2. GlcNAc Transferases
- 7.2.1.2.1. Acetylglucosaminyltransferase
- 7.2.1.2.2. Exostosin
- 7.2.1.2.3. Others
- 7.2.1.3. Fucosyltransferases
- 7.2.1.4. GalNAc Transferases
- 7.2.1.5. Galactosyl Transferases
- 7.2.1.6. Glucuronosyltransferases
- 7.2.1.7. Glucosyltransferases
- 7.2.1.8. Pentosyltransferases
- 7.2.1.9. Carbohydrate Kinases
- 7.2.1.10. Neuraminidases
- 7.2.1.11. Sialyltransferases
- 7.2.1.12. Others
- 7.3. Latin America Glycobiology Market Outlook, by Application, Value (US$ Bn), 2019-2032
- 7.3.1. Key Highlights
- 7.3.1.1. Drug Discovery and Development
- 7.3.1.2. Diagnostic Applications
- 7.3.1.2.1. Oncology
- 7.3.1.2.2. Immunology
- 7.3.1.2.3. Others
- 7.3.1.3. Industrial Applications
- 7.3.1.4. Therapeutic Applications
- 7.3.1.4.1. Oncology
- 7.3.1.4.2. Immunology
- 7.3.1.4.3. Others
- 7.3.1.5. Others
- 7.4. Latin America Glycobiology Market Outlook, by End User, Value (US$ Bn), 2019-2032
- 7.4.1. Key Highlights
- 7.4.1.1. Biopharmaceutical Companies
- 7.4.1.2. Research Laboratories
- 7.4.1.3. Hospitals
- 7.4.1.4. Diagnostic Centers
- 7.4.1.5. Contract Research Organizations
- 7.4.1.6. Biotechnology Industries
- 7.4.1.7. Academic Institutes
- 7.4.1.8. Others
- 7.5. Latin America Glycobiology Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 7.5.1. Key Highlights
- 7.5.1.1. Brazil Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 7.5.1.2. Brazil Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 7.5.1.3. Brazil Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 7.5.1.4. Brazil Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 7.5.1.5. Mexico Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 7.5.1.6. Mexico Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 7.5.1.7. Mexico Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 7.5.1.8. Mexico Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 7.5.1.9. Argentina Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 7.5.1.10. Argentina Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 7.5.1.11. Argentina Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 7.5.1.12. Argentina Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 7.5.1.13. Rest of Latin America Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 7.5.1.14. Rest of Latin America Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 7.5.1.15. Rest of Latin America Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 7.5.1.16. Rest of Latin America Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 7.5.2. BPS Analysis/Market Attractiveness Analysis
- 8. Middle East & Africa Glycobiology Market Outlook, 2019-2032
- 8.1. Middle East & Africa Glycobiology Market Outlook, by Product, Value (US$ Bn), 2019-2032
- 8.1.1. Key Highlights
- 8.1.1.1. Instruments
- 8.1.1.2. Enzymes
- 8.1.1.3. Consumables
- 8.1.1.4. Kits and Reagents
- 8.2. Middle East & Africa Glycobiology Market Outlook, by Enzyme, Value (US$ Bn), 2019-2032
- 8.2.1. Key Highlights
- 8.2.1.1. Galactosidases
- 8.2.1.1.1. Fucosidases
- 8.2.1.1.2. Chitinases
- 8.2.1.1.3. Acetylgalactosaminidase
- 8.2.1.1.4. Heparinase
- 8.2.1.1.5. PNGase F
- 8.2.1.1.6. Others
- 8.2.1.2. GlcNAc Transferases
- 8.2.1.2.1. Acetylglucosaminyltransferase
- 8.2.1.2.2. Exostosin
- 8.2.1.2.3. Others
- 8.2.1.3. Fucosyltransferases
- 8.2.1.4. GalNAc Transferases
- 8.2.1.5. Galactosyl Transferases
- 8.2.1.6. Glucuronosyltransferases
- 8.2.1.7. Glucosyltransferases
- 8.2.1.8. Pentosyltransferases
- 8.2.1.9. Carbohydrate Kinases
- 8.2.1.10. Neuraminidases
- 8.2.1.11. Sialyltransferases
- 8.2.1.12. Others
- 8.3. Middle East & Africa Glycobiology Market Outlook, by Application, Value (US$ Bn), 2019-2032
- 8.3.1. Key Highlights
- 8.3.1.1. Drug Discovery and Development
- 8.3.1.2. Diagnostic Applications
- 8.3.1.2.1. Oncology
- 8.3.1.2.2. Immunology
- 8.3.1.2.3. Others
- 8.3.1.3. Industrial Applications
- 8.3.1.4. Therapeutic Applications
- 8.3.1.4.1. Oncology
- 8.3.1.4.2. Immunology
- 8.3.1.4.3. Others
- 8.3.1.5. Others
- 8.4. Middle East & Africa Glycobiology Market Outlook, by End User, Value (US$ Bn), 2019-2032
- 8.4.1. Key Highlights
- 8.4.1.1. Biopharmaceutical Companies
- 8.4.1.2. Research Laboratories
- 8.4.1.3. Hospitals
- 8.4.1.4. Diagnostic Centers
- 8.4.1.5. Contract Research Organizations
- 8.4.1.6. Biotechnology Industries
- 8.4.1.7. Academic Institutes
- 8.4.1.8. Others
- 8.5. Middle East & Africa Glycobiology Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 8.5.1. Key Highlights
- 8.5.1.1. GCC Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 8.5.1.2. GCC Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 8.5.1.3. GCC Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 8.5.1.4. GCC Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 8.5.1.5. South Africa Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 8.5.1.6. South Africa Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 8.5.1.7. South Africa Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 8.5.1.8. South Africa Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 8.5.1.9. Egypt Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 8.5.1.10. Egypt Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 8.5.1.11. Egypt Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 8.5.1.12. Egypt Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 8.5.1.13. Nigeria Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 8.5.1.14. Nigeria Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 8.5.1.15. Nigeria Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 8.5.1.16. Nigeria Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 8.5.1.17. Rest of Middle East & Africa Glycobiology Market by Product, Value (US$ Bn), 2019-2032
- 8.5.1.18. Rest of Middle East & Africa Glycobiology Market Indication, Value (US$ Bn), 2019-2032
- 8.5.1.19. Rest of Middle East & Africa Glycobiology Market Artery Type, Value (US$ Bn), 2019-2032
- 8.5.1.20. Rest of Middle East & Africa Glycobiology Market End User, Value (US$ Bn), 2019-2032
- 8.5.2. BPS Analysis/Market Attractiveness Analysis
- 9. Competitive Landscape
- 9.1. Artery Type vs Indication Heatmap
- 9.2. Manufacturer vs Indication Heatmap
- 9.3. Company Market Share Analysis, 2025
- 9.4. Competitive Dashboard
- 9.5. Company Profiles
- 9.5.1. Glycodiag
- 9.5.1.1. Company Overview
- 9.5.1.2. Product Portfolio
- 9.5.1.3. Financial Overview
- 9.5.1.4. Business Strategies and Development
- 9.5.2. Tracxn Technologies Limited
- 9.5.2.1. Company Overview
- 9.5.2.2. Product Portfolio
- 9.5.2.3. Financial Overview
- 9.5.2.4. Business Strategies and Development
- 9.5.3. Agilent Technologies, Inc.
- 9.5.3.1. Company Overview
- 9.5.3.2. Product Portfolio
- 9.5.3.3. Financial Overview
- 9.5.3.4. Business Strategies and Development
- 9.5.4. Takara Bio Inc.
- 9.5.4.1. Company Overview
- 9.5.4.2. Product Portfolio
- 9.5.4.3. Financial Overview
- 9.5.4.4. Business Strategies and Development
- 9.5.5. Bio-Techne
- 9.5.5.1. Company Overview
- 9.5.5.2. Product Portfolio
- 9.5.5.3. Financial Overview
- 9.5.5.4. Business Strategies and Development
- 9.5.6. Bruker Corporation
- 9.5.6.1. Company Overview
- 9.5.6.2. Product Portfolio
- 9.5.6.3. Financial Overview
- 9.5.6.4. Business Strategies and Development
- 9.5.7. Thermo Fisher Scientific Inc.
- 9.5.7.1. Company Overview
- 9.5.7.2. Product Portfolio
- 9.5.7.3. Financial Overview
- 9.5.7.4. Business Strategies and Development
- 9.5.8. Shimadzu Corporation
- 9.5.8.1. Company Overview
- 9.5.8.2. Product Portfolio
- 9.5.8.3. Financial Overview
- 9.5.8.4. Business Strategies and Development
- 9.5.9. New England Biolabs.
- 9.5.9.1. Company Overview
- 9.5.9.2. Product Portfolio
- 9.5.9.3. Financial Overview
- 9.5.9.4. Business Strategies and Development
- 9.5.10. Waters.co.
- 9.5.10.1. Company Overview
- 9.5.10.2. Product Portfolio
- 9.5.10.3. Financial Overview
- 9.5.10.4. Business Strategies and Development
- 9.5.11. Merck KGaA
- 9.5.11.1. Company Overview
- 9.5.11.2. Product Portfolio
- 9.5.11.3. Financial Overview
- 9.5.11.4. Business Strategies and Development
- 9.5.12. Palleon Pharmaceuticals
- 9.5.12.1. Company Overview
- 9.5.12.2. Product Portfolio
- 9.5.12.3. Financial Overview
- 9.5.12.4. Business Strategies and Development
- 9.5.13. Asparia Glycomics
- 9.5.13.1. Company Overview
- 9.5.13.2. Product Portfolio
- 9.5.13.3. Financial Overview
- 9.5.13.4. Business Strategies and Development
- 9.5.14. RayBiotech Life,Inc.
- 9.5.14.1. Company Overview
- 9.5.14.2. Product Portfolio
- 9.5.14.3. Financial Overview
- 9.5.14.4. Business Strategies and Development
- 9.5.15. Z Biotech,LLC.
- 9.5.15.1. Company Overview
- 9.5.15.2. Product Portfolio
- 9.5.15.3. Financial Overview
- 9.5.15.4. Business Strategies and Development
- 9.5.16. Chemily Glycoscience
- 9.5.16.1. Company Overview
- 9.5.16.2. Product Portfolio
- 9.5.16.3. Financial Overview
- 9.5.16.4. Business Strategies and Development
- 9.5.17. Lectenz Bio
- 9.5.17.1. Company Overview
- 9.5.17.2. Product Portfolio
- 9.5.17.3. Financial Overview
- 9.5.17.4. Business Strategies and Development
- 9.5.18. Nano Therapeutics Pvt. Ltd.
- 9.5.18.1. Company Overview
- 9.5.18.2. Product Portfolio
- 9.5.18.3. Financial Overview
- 9.5.18.4. Business Strategies and Development
- 9.5.19. 2BScientific
- 9.5.19.1. Company Overview
- 9.5.19.2. Product Portfolio
- 9.5.19.3. Financial Overview
- 9.5.19.4. Business Strategies and Development
- 10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
